Theravance Biopharma, Inc. (TBPH) Income Statement
TBPH 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTBPH revenue and net income
Where TBPH's revenue goes
2025Each bar shows an amount and its share of revenue. TBPH kept 98.5% of revenue as net income.
TBPH profit margins
TBPH growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +66.9% | +27.9% | +8.4% | +9.8% |
| Gross profit | +281.3% | — | +7.2% | +10.5% |
| Operating income | — | — | — | — |
| Net income | — | −50.5% | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TBPH quarterly EPS vs estimates
Theravance Biopharma beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 9, 2026 (estimate $0.19).
TBPH income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $107.5M | $64.4M | $57.4M | $51.3M | $55.3M | $71.9M | $73.4M | $60.4M | $15.4M | $48.6M |
| Cost of revenue | $5.5M | $37.6M | $40.6M | $63.4M | $193.7M | $261.0M | $219.2M | $715,000 | $6.0M | $2.9M |
| Gross profit | $101.9M | $26.7M | $16.8M | −$12.0M | −$138.3M | $71.9M | $73.4M | $59.7M | $9.4M | $45.8M |
| Research & development | $37.4M | $38.0M | $46.3M | $70.1M | $201.5M | $261.0M | $219.2M | $201.3M | $173.9M | $141.7M |
| Sales, general & admin | $73.7M | $64.9M | $65.4M | $59.1M | $99.3M | $108.7M | $106.1M | $97.1M | $95.6M | $84.5M |
| Total operating expenses | $115.2M | $73.7M | $72.8M | $79.9M | $119.4M | $369.5M | $325.3M | $298.4M | $269.5M | $226.2M |
| Operating income | −$13.2M | −$46.9M | −$56.0M | −$92.0M | −$257.8M | −$297.6M | −$251.9M | −$238.8M | −$260.1M | −$180.5M |
| Interest income | $10.2M | $4.9M | $11.0M | $8.5M | $1.1M | $2.8M | $8.4M | $12.0M | $5.0M | $1.3M |
| Interest expense | $2.5M | $2.5M | $2.4M | $6.4M | $8.5M | $8.5M | $31.9M | $10.5M | $8.5M | $1.4M |
| Income before taxes | $129.2M | −$44.6M | −$49.3M | −$92.8M | −$265.2M | −$303.3M | −$241.7M | −$226.1M | −$271.7M | −$180.6M |
| Income taxes | $23.4M | $11.8M | $5.9M | $9,000 | −$151,000 | −$8.5M | −$5.2M | −$10.6M | $13.7M | $10.1M |
| Net income | $105.9M | −$56.4M | −$55.2M | $872.1M | −$199.4M | −$278.0M | −$236.5M | −$215.5M | −$285.4M | −$190.7M |
| EBITDA | $137.2M | −$38.5M | −$49.4M | −$72.1M | −$229.0M | −$287.8M | −$203.6M | −$212.4M | −$259.1M | −$176.0M |
| EPS (diluted) | $1.01 | −$0.33 | −$0.35 | −$0.38 | −$2.93 | −$4.22 | −$4.26 | −$4.00 | −$5.45 | −$4.25 |
| Gross margin | 94.9% | 41.5% | 29.3% | −23.5% | −250.1% | 100.0% | 100.0% | 98.8% | 60.8% | 94.1% |
| Operating margin | −12.3% | −72.9% | −97.6% | −179.1% | −466.1% | −414.2% | −343.1% | −395.5% | −1,690.6% | −371.0% |
| Net margin | 98.5% | −87.6% | −96.1% | 1,698.5% | −360.6% | −386.9% | −322.1% | −357.0% | −1,855.0% | −391.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.7M | $17.7M | $45.9M | $20.0M | $26.2M | $15.4M | $18.8M | $16.9M | $14.3M | $14.5M | $17.6M | $15.7M |
| Cost of revenue | $1.4M | $1.4M | $1.5M | $8.1M | $10.5M | $11.5M | $9.5M | $9.3M | $10.0M | $9.0M | $8.3M | $1.3M |
| Gross profit | $19.3M | $17.7M | $44.4M | $11.9M | $15.7M | $3.9M | $9.3M | $7.6M | $4.3M | $5.5M | $9.3M | $14.4M |
| Research & development | $4.7M | $5.8M | $7.0M | $8.1M | $10.5M | $11.5M | $9.4M | $9.3M | $10.0M | $9.0M | $9.0M | $7.9M |
| Sales, general & admin | $14.2M | $17.7M | $18.5M | $18.3M | $18.4M | $18.4M | $14.2M | $16.9M | $17.1M | $16.7M | $10.7M | $16.1M |
| Total operating expenses | $19.9M | $23.5M | $26.8M | $18.3M | $18.4M | $18.4M | $18.5M | $18.4M | $20.0M | $16.7M | $15.5M | $23.1M |
| Operating income | −$604,000 | −$5.8M | $17.6M | −$6.5M | −$2.7M | −$14.4M | −$9.2M | −$10.8M | −$15.7M | −$11.2M | −$6.2M | −$8.8M |
| Interest income | $3.5M | $3.0M | $3.6M | $4.1M | $1.5M | $939,000 | $904,000 | $1.4M | $1.1M | $1.4M | $1.8M | $1.8M |
| Interest expense | $0 | $0 | $583,000 | $573,000 | $663,000 | $643,000 | $643,000 | $630,000 | $644,000 | $629,000 | $623,000 | $609,000 |
| Income before taxes | −$4.8M | −$6.5M | $73.1M | −$2.9M | $73.2M | −$14.1M | −$8.9M | −$10.1M | −$15.2M | −$10.4M | −$5.0M | −$7.6M |
| Income taxes | $1.1M | −$1.5M | $12.0M | −$6.5M | $18.4M | −$559,000 | $6.6M | $2.6M | $1.3M | $1.3M | $3.5M | $1.4M |
| Net income | −$5.9M | −$4.9M | $61.0M | $3.6M | $54.8M | −$13.6M | −$15.5M | −$12.7M | −$16.5M | −$11.7M | −$8.5M | −$8.9M |
| EBITDA | $839,000 | −$5.6M | $75.2M | −$1.7M | $74.8M | −$12.4M | −$7.6M | −$8.5M | −$11.8M | −$8.6M | −$5.2M | −$5.6M |
| EPS (diluted) | $0.07 | $0.01 | $0.06 | $0.04 | $1.08 | −$0.17 | −$0.05 | −$0.06 | −$0.13 | −$0.09 | $0.03 | −$0.01 |
| Gross margin | 93.0% | 100.0% | 96.7% | 59.4% | 60.0% | 25.6% | 49.6% | 45.1% | 30.2% | 38.2% | 52.7% | 91.5% |
| Operating margin | −2.9% | −33.1% | 38.3% | −32.3% | −10.4% | −93.8% | −49.1% | −64.2% | −110.2% | −77.3% | −35.5% | −55.8% |
| Net margin | −28.5% | −27.9% | 133.0% | 18.1% | 209.3% | −88.2% | −82.8% | −75.3% | −115.9% | −80.4% | −48.4% | −57.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TBPH's financial statements (latest annual report filed March 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TBPH financial results
In fiscal year 2025 (ended December 31, 2025), Theravance Biopharma reported revenue of $107.5 million, up 66.9% from the year before. It had net income of $105.9 million, a net profit margin of 98.5%. Diluted earnings per share came to $1.01. Over five years revenue grew at an average rate of 8.4% a year.
See the TBPH stock overview for the latest quote and news, or the TBPH chart for price history and technical indicators.
TBPH income statement FAQ
What is Theravance Biopharma's annual revenue?
Theravance Biopharma reported total revenue of $107.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 66.9% from $64.4 million the previous year.
Is Theravance Biopharma profitable?
Yes. Theravance Biopharma reported net income of $105.9 million in fiscal 2025, a net profit margin of 98.5%; its operating margin was −12.3%.
What is Theravance Biopharma's gross margin?
Theravance Biopharma's gross margin was 94.9% in fiscal 2025: for every $100 of revenue, Theravance Biopharma kept $95 after the direct cost of its products and services.
How much does Theravance Biopharma spend on research and development?
Theravance Biopharma spent $37.4 million on research and development in fiscal 2025, 34.8% of revenue.
How fast is Theravance Biopharma growing?
Revenue grew 8.4% a year on average over the last five fiscal years, from $71.9 million to $107.5 million.
What are Theravance Biopharma's earnings per share?
Theravance Biopharma earned $1.01 per diluted share in fiscal 2025, compared with $-0.33 a year earlier.
When will Theravance Biopharma report its next earnings?
Theravance Biopharma is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Theravance Biopharma's fiscal year end?
Theravance Biopharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 23, 2026.